Introduction
cess is dependent on MHC class II presentation of the E1-deleted replication-defective adenoviral (Ad) vectors input viral proteins and activation of CD4 + T cells and are attractive vehicles for gene transfer because of their can be induced by inactive as well as active viral parability to transduce a wide variety of dividing and nonticles, 6 (Kaplan et al, unpublished data). dividing cells in vivo.
1-5 Such vectors have been used for Several investigators have tested the use of broad gene transfer to the respiratory epithelium of experiimmunosuppressants 11 and cytoablative agents 16 to overmental animals and of individuals with cystic fibrosis come the immune response of the host to first generation (CF).
2-5 Studies from several laboratories have suggested Ad vectors. Kay et al 17 have shown that transient coadthat administration of high doses of first generation Ad ministration of soluble CTLA4-Ig along with an intravector results in only transient gene expression in the venous injection of Ad vector expressing a nonimmunolung due, at least in part, to destruction of vector-transgenic transgene product (human ␣-1 anti-trypsin) leads duced cells by host cellular immune responses to persistent transgene expression from mouse liver. (predominantly CD8
+ cytotoxic T cells) directed against CTLA4-Ig blocks the B7-CD28 pathway of T cell costimuviral proteins and/or immunogenic transgene products. [6] [7] [8] [9] lation. 18 Although Ad-specific antibody levels were Reduction of this response has been reported following reduced in CTLA4-Ig-treated mice, the inhibition was not the use of second generation vectors with decreased viral sufficient to allow secondary gene transfer under the congene expression 10,11 and with transgenes encoding self ditions tested. 17 Yang et al 19 demonstrated that coadminrather than foreign proteins.
istration of interferon-␥ (INF-␥) or interleukin-12 (IL-12)
The treatment of chronic diseases like CF with Ad vecwith recombinant Ad vector diminished the formation of tors will likely require repeated administrations throughneutralizing antibodies and allowed readministration of out the lifetime of the patient. However, another limivector to mouse airways. However, IL-12 is a potent tation of current vectors is the difficulty in obtaining mediator which affects Th1 type CD4 + T cell responses successful readministration using a vector of the same Ad and is involved in stimulating natural killer cells and proserotype. Several groups have now demonstrated that a moting the differentiation of cytotoxic T cells. [20] [21] [22] INF-␥ strong dose-dependent humoral immune response is is known to up-regulate MHC class I on antigen induced by Ad vectors leading to the development of presenting cells. 23 Thus, both INF-␥ and IL-12, while capneutralizing antibodies to adenoviruses.
6,7,12-15 Studies able of inhibiting humoral immunity, might enhance the elimination of Ad vector-transduced cells by CTLs. Activated T cells play a critical role in the generation of humoral and cellular immune responses. The interaction of an antigen presenting cell (APC) is necessary but not sufficient for the optimal activation of T cells which also requires additional costimulatory signals provided by several receptor-ligand pairs including B7-CD28 and CD40-CD40 ligand (CD40L).
18 CD40L is expressed transiently at high levels on activated CD4 + T cells. 24, 25 The costimulation provided by CD40L on T cells interacting with CD40 on B cells and other APCs seems to be essential for thymus-dependent humoral immunity [25] [26] [27] [28] and may also play an important role in the generation of cellular immune responses through the production of helper cytokines. [28] [29] [30] In this article, we describe experiments aimed at blocking this costimulation pathway transiently using a monoclonal antibody against CD40L. The results of these experiments show that, in the context of administration of an Ad vector to mouse airways, anti-CD40L inhibited both humoral and cellular immune responses.
Results
Anti-CD40 ligand suppresses development of Ad-specific antibodies To explore the role of the CD40-CD40L interaction in the generation of antibodies to Ad vectors, BALB/c mice were injected intraperitoneally with anti-CD40L monoclonal antibody (MR1, 200 g/injection per mouse on days −2, +2, +6 and +10). Ad2/CFTR2 vector (10 9 IU) was instilled intranasally on day 0. Analysis of serum from these animals by ELISA showed a marked decrease in anti-Ad (IgG + IgM + IgA) titers in MR1-treated mice for up to 41 days ( Figure 1a) . Analysis of bronchoalveolar lavage (BAL) fluid revealed a parallel drop in Ad-specific IgA levels in MR1-treated mice (Figure 1b) .
On day 38 after the first administration of Ad2/CFTR2, a vector of the same serotype, Ad2/␤Gal2, was administered to the different groups of mice. Expression of ␤-galactosidase was measured by a quantitative assay on Ad2/␤Gal-4 on day 0 and injected with MR1 on days −2, +2, +5 and +8. As shown in Figure 3a , spleen cells from MR1-treated mice showed decreased yet measurable levcharacterized by inflammatory cell infiltrates was present on day 5 and was not yet resolved at day 21. On day 5, els of CTL activity compared with spleen cells from untreated control mice, albeit using an assay that is not there were no differences noted between the lungs of mice treated with the vector either with or without MR1 strictly quantitative.
Since CTLs have been implicated in the loss of transantibody treatment (data not shown). However, on day 21, there were fewer inflammatory changes in all regions gene expression, we tested whether administration of MR1 with an Ad vector would give rise to prolonged of the lungs from mice treated with the antibody ( Figure  4 ). The inflammatory cell infiltrate was markedly reduced transgene expression. As shown in Figure 3b , transgene expression measured by a quantitative galactosidase in the peribronchial/peribronchiolar and perivascular regions. assay, declined to background levels by day 21 in the untreated controls. By comparison, in MR1-treated mice, transgene expression also declined but remained consistSecondary antibody response in a preimmunized host MR1 was tested for its ability to interfere with the secently higher than in untreated mice.
Lung tissue from the mice was examined for evidence ondary antibody response in mice that had been preimmunized with Ad vector. Mice were instilled with 10 8 IU of histopathological changes in the peribronchial, perivascular and alveolar regions. Lung inflammation of Ad2/CFTR2 on day 0 and readministered with 10 8 IU of Ad2/CFTR2 on day 50. We had previously determined that an intranasal instillation of 10 8 IU of Ad vector elicits both humoral and cellular immune responses to the vector in several strains of mice including BALB/c (data not shown). MR1 injections were given around the time of the second virus administration on days 44, 48, 52 and 56. Sera from the different groups of animals were analyzed both for anti-Ad ELISA titers (IgG + IgM + IgA) and Ad neutralizing titers at various time-points. The secondary antibody response measured by ELISA was only slightly decreased in the MR1-treated mice but was less sustained (Figure 5a ). The antibody titers declined more rapidly and by the time of the third vector administration on day 99, both the ELISA titers and Ad neutralizing titers were clearly decreased in the mice that had received MR1 along with the second administration of Ad vector (Figure 5a and b) .
The ␤-galactosidase encoding Ad2/␤Gal-2 vector was given as the third administration on day 99 and ␤-galactosidase levels in the lung were measured 3 days later on day 102. Control mice that had received the first (day 0) and second dose (day 50) of Ad2/CFTR2 showed only 6% of the ␤-galactosidase activity in lung homogenates compared with naive mice that received a single intranasal administration of Ad2/␤Gal-2 (Figure 6 ). Mice that received MR1 around the time of the second administration of Ad2/CFTR2 showed 10-fold higher levels of Ad-based gene therapy for genetic diseases such as cystic fibrosis will likely require repeated administrations due to the transient nature of transgene expression from cura clinical reality. We and others 6,7,13,14 have shown that administration of Ad vectors to the airways leads to the rent vectors. While improvements in vector design should increase persistence of expression to some degree, activation of Ad-specific T and B cells. The cellular immune response includes CD8 + T cells which, in many the barrier of humoral immunity against Ad also needs to be overcome before Ad-based gene therapy becomes animal models, appear to be involved in the rapid decline in transgene expression.
6-9
The humoral immune response, which is dependent on MHC class II-mediated antigen presentation to CD4 + T cells, 6 promotes the generation of Ad-specific neutralizing antibodies of both IgA and IgG isotypes.
14 This serotype-specific antibody response correlates with the reduced effectiveness of repeated administrations of a vector of the same serotype. 15 In this article, we demonstrate that a transient blockade of costimulation between T cells and B cells and other APCs using a monoclonal antibody (MR1) against CD40 ligand suppresses the development of antibodies against Ad and allows for efficient readministration of vector. MR1 treatment partially decreased the cellular immune response to Ad vector and this correlated with an increase in persistence of transgene expression. As expected, MR1 treatment did not affect the nonspecific acute phase of inflammation induced by intranasal administration of Ad vector (day 5, not shown), but the 
by ELISA. Data are presented as the mean titer of four individual animals
Most CF patients will have been exposed to human of adenovirus to which they have been exposed. It is
possible that the pre-existing anti-Ad humoral immunity in these individuals might interfere with a single or repeated Ad vector administration. To test this directly, we studied gene expression in mice that were already allografts. 35 In models of acute GVHD, it has been shown that anti-CD40L can completely block the generation of immunized against Ad vector. We found that coadministration of MR1 inhibited the development and persistence anti-host CTL responses. It has been proposed that this is due to the ability of anti-CD40L to interfere with the of a secondary antibody response and resulted in high levels of transgene expression upon a third adminismaturation of professional APC so that they do not acquire appropriate costimulatory molecules optimally to tration of vector to the airway. This finding is consistent with reports that CD40L is critical for formation of germipresent antigen. 36 Recent studies confirm that CD40 may play an important role in dendritic cell function 37 and nal centers as well as their maintenance. 31, 32 Recent studies in animal models have shown that treattherefore impact on the priming of T cells. 38 In this study, we have demonstrated the inhibitory effect of MR1 on ment with anti-CD40L in vivo can block the development of collagen-induced arthritis 33 and graft-versus-host dishumoral and cellular immune responses against Ad vectors for several weeks after the last administration of ease (GVHD) 34 and prevent rejection of pancreatic islet MR1, at which time less than 2% of biologically active
Adenoviral vectors
The construction of Ad2/CFTR2 and Ad2/␤Gal-2 has MR1 should still be present in the serum. 25 It therefore appears possible to readminister an Ad vector using been described previously. 7 They are both Ad2-based vectors with most of the E1 region deleted and replaced a transient blockade of T cell costimulation without complete immunosuppression of the host for prolonged with the transgene and the E4 region replaced with the open reading frame 6 (ORF6) of E4. Ad2/␤Gal-4 is identperiods of time.
Since it is known that several interactions including ical to Ad2/␤Gal-2 except that it contains the complete wild-type E4 region. both B7-CD28 and CD40-CD40L are essential for optimal costimulation between T cells and APC, 18 ,28,39 a combined Histopathology therapy with CTLA4Ig and MR1 might be even more On the day of death, mice were killed with an IP injection effective. Although the practicability of coadministration of Somlethal (Euthasol; King Pharmaceuticals, Bristol, of viral vectors and humanized recombinant antibodies TN, USA). The lungs were cleared of blood by vascular to CF patients is questionable, such studies have and will perfusion with phosphate-buffered saline (PBS). The trareveal more details about the process of immune recogchea was cannulated and the lungs and trachea removed. nition of Ad vectors and may suggest simpler strategies The lungs were fixed by inflation with 2% paraformalto block that process. dehyde with 0.2% glutaraldehyde in PBS, pH 7.4, at a pressure of 30 cm of H 2 O. Following overnight fixation, portions of the left lung were embedded in glycometh-
Materials and methods
acrylate, sectioned and stained with hematoxylin and eosin. These sections were evaluated by light microscopy Antibody injections MR1, a hamster anti-mouse CD40 ligand monoclonal for the presence and distribution of lung inflammation without previous knowledge of treatment. 40 The lung antibody was produced in ascites and purified by ion exchange HPLC as previously described. 24 BALB/c mice sections were subjectively assessed for morphologic alterations on a scale of 0-4: 0 = no lesion, 1 = minimal, 2 = were purchased from Taconic (Germantown, NY, USA) and were typically injected intraperitoneally (IP) with a mild, 3 = moderate, 4 = severe. total of four injections of 200 or 250 g of MR1/mouse Adenovirus-specific antibodies starting on day −2 relative to the time of administration Titers of Ad-specific serum antibodies were evaluated by of the Ad vector.
ELISA. Serial two-fold dilutions of sample were added to To determine neutralizing antibody titers, serial two-fold The titer was defined as the reciprocal of the highest dilutions of sample were incubated with live Ad2/CFTRdilution of sample which produced an OD 490 greater 2 for 1 h at 37°C/5% CO 2 in the wells of flat-bottom 96-than 0.1. well plates. At the end of the incubation period, permissTo evaluate levels of Ad-specific IgA in BAL, samples ive 293 cells were added to the wells and the plates were were diluted two-fold and added to Ad2-coated plates incubated at 37°C/5% CO 2 for 72-96 h. The assay was followed by the addition of HRP-conjugated goat antiread when control 293 cells incubated alone reached mouse IgA (␣ chain-specific; Cappel, Durham, NC, USA).
у90% confluency. The neutralizing antibody titer was For quantification, a standard curve was constructed defined as the reciprocal of the highest dilution of sample using a monoclonal antibody against mouse IgA (Harlan that showed any detectable protection of 293 cells from Sera-Lab, Sussex, UK) to coat ELISA plates and capture cytopathic effects when compared with cells incubated known amounts of purified mouse IgA (Cappel). The with untreated virus or virus incubated with sero-OD 490 values obtained following the addition of HRPnegative serum. conjugated goat anti-mouse IgA were plotted against the amounts of IgA standard (ng/ml) added to the wells. The
